Rubicon Organics Inc.
ROMJF • Drug Manufacturers - Specialty & Generic
$0.36
▼ -0.01 (-1.53%)
Current price
EarningsLatest report: Mar 31, 2026
BALANCED PROFILENeutralConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$25.43M
Growth
6.2%
Cash Flow
2/5
Trend
Volatile
Evidence
Positive revenue growth · 21.6%Manageable debt level · 0.28Healthy liquidity · 2.94
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 14, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.36
Change-1.53%
Shares Out70.43M
Market Cap$25.43M
52W Range0.27 - 0.54
Beta0.47
P/E-3.58
P/S2.88
P/B0.95
P/FCF-126.58
EV/Sales3.30
EV/EBITDA-7.27
Price$0.36
Change-1.53%
Shares Out70.43M
Market Cap$25.43M
52W Range0.27 - 0.54
Beta0.47
P/E-3.58
P/S2.88
P/B0.95
P/FCF-126.58
EV/Sales3.30
EV/EBITDA-7.27
EV/FCF-145.11
Earnings Yield-6.99%
FCF Yield-0.79%
Dividend Yield0.00%
Gross Margin-11.42%
Oper. Margin-25.79%
Profit Margin1.77%
Debt/Eq0.28
Current Ratio2.94
Quick Ratio1.34
Revenue 5Y6.18%
Volume0.00
Avg Volume28.74K
EPS Surprise-0.01
Investment DNA
How strong this company looks for long-term investors
55
out of 100
Business Quality
Margins, moat, returns
40/100
Financial Strength
Debt, cash, stability
74/100
Growth Potential
Revenue and expansion
58/100
Price Attractiveness
Cheap or expensive today
75/100
Why this score▼
Positive revenue growth · 21.6%Manageable debt level · 0.28Healthy liquidity · 2.94
Analyst view
No analyst data available now.
🧾
No insider activity
No recent insider transactions available.